Alliance Pharma Share Discussion Threads

[blackhorse23] 18/4/2024 12:23

AlliancePharma will be publishing FY results on 23 April, details provided in its trading update in Jan "remain accurate", reported revenues £182.7m for 2023,up 6%

[maverick67] 18/4/2024 11:57

Oh shut up you moron!! Stop posting on other boards and il stop here

[tomzimerman] 18/4/2024 10:48

Can't be bothered with this anymore, life's too short, there's always another bus going higher and in different directions. I wish genuine holders well here and hope the results come good for those in already. A little bit of advice, whether you down vote me or not I won't be surprised but genuinely your posts put investors off and although you may think spamming every board with the same posts it has the opposite effect which has been plainly obvious. You do what you want take my advice or ignore it and carry on. Perhaps a more constructive balanced approach as you obviously do know the markets well would help Good luck

[blackhorse23] 18/4/2024 10:28

Financial summary for NEXT WEEK: The Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations.

[blackhorse23] 18/4/2024 09:20

AlliancePharma has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEND +5% -PORTFOLIO BROADENED THROUGH ACQUISITION

[blackhorse23] 17/4/2024 21:37

Cash and debtFree cash flow in the Period rose 34% to £21.1m (FY22: £15.8m) and net debt reduction continued, falling to £92.4m at 31 December 2023 (31 December 2022: £102.0m). Group leverage2 (as at 31 December 2023) is expected to be significantly below that at 30 June 2023 (2.7x), and in-line with previous guidance.

[maverick67] 17/4/2024 20:32

Next rns good sales but we have increased debt to 180 mil sorry no div as we have to pay some debt off

[maverick67] 17/4/2024 20:28

140 million in debt high interest rates no divi expected

[tomzimerman] 17/4/2024 12:40

Yes what was it 30-40 percent uplift on results day you told that poor jerry You and your mates can down vote me all you like, truths coming out for all to see soon.

[blackhorse23] 17/4/2024 09:45

APH most of the business outside UK , revenue & profits will be up by 10% on next week FY results according to last month trading update RNS

[tomzimerman] 17/4/2024 08:48

Yes actually some good news out the uk regarding the economy today, may make this attractive soon and help relieve debt burdens, I don't hold here and don't short stocks ever, however I am interested but will wait until after the results and see what the outlook from the company is on results day. Good luck to all holder expect black donkey who is obviously constantly trading this and spamming everyone and everywhere.

[blackhorse23] 17/4/2024 08:30

Bought the dips

[blackhorse23] 16/4/2024 16:06

You need medicine from alliance pharma for mental health

[maverick67] 16/4/2024 15:57

Only thing with this is down down....enquest up and up.. oil price looking strong

[maverick67] 16/4/2024 15:56

Sold more bought enquest

[blackhorse23] 16/4/2024 15:18

Added more at this dip

[buoycat] 16/4/2024 13:40

As a long term holder, not looking strong at the moment.

[blackhorse23] 16/4/2024 09:42

Looking strong before the result day

[maverick67] 16/4/2024 09:15

No Divi sell move money elsewhere

[blackhorse23] 15/4/2024 13:26

NET ASSET VALUE: 51p* & share prices currently 37.50 , BARGAIN BUY

[blackhorse23] 15/4/2024 13:25

Pharma (APH) is relying on a strong second half to drive growth following six hit-and-miss months. The group is still in the process of steadying itself after a few quarters of disruption both within the organisation and in its key markets. important revenue driver for the company, which is best known for its Kelo-cote scar prevention franchise.

[blackhorse23] 15/4/2024 10:26

Next Tuesday results day will be double from here , encouraging results

[trustman] 15/4/2024 10:05

Does restoration of Peter Butterfield as CEO mean CMA are happy with him?